« Previous
Next »
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1
, Pages
30-37
, January 2008
One-week dose titration of extended release galantamine in patients with Alzheimer’s disease
To access this article, please choose from the options below
Financial disclosures: Douglas W. Scharre, M.D., serves as a consultant and speaker for Abbott Laboratories, Eisai, Inc., Forest Laboratories, Ortho-McNeil Janssen, and Pfizer, Inc. He has received research grants from Astellas Pharma, Inc., Eisai, Inc., Forest Laboratories, GlaxoSmithKline, Janssen Pharmaceutica, Myriad Genetics, Inc., Ono Pharmaceutical, Pfizer, Inc., Sanofi-Aventis Pharmaceuticals, and Voyager. Thomas Shiovitz, M.D., serves as a consultant and speaker for Pfizer, Inc. He has received research grants from Astellas Pharma, Inc., Astra-Zeneca, Corcept, Eisai, Inc., Janssen Pharmaceutica, Lilly, Merck, Pfizer, Inc., Sanofi-Aventis Pharmaceuticals, and Sention. Young Zhu, Ph.D., and Joan Amatniek, M.D., are employees of Ortho-McNeil Janssen Scientific Affairs, L.L.C.
PII: S1552-5260(07)00638-3
doi: 10.1016/j.jalz.2007.10.013
© 2008 The Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1
, Pages
30-37
, January 2008
